Cancer Immunotherapy: Challenges and Opportunities

Cancer Immunotherapy

Volumn , Issue , 2007, Pages 167-181

  Lepisto, Andrew J ^a   Mckolanis, John R ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953808313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012372551-6/50074-2     Document Type: Chapter

References (75)

1. Aalamian M., Tourkova I.L., Chatta G.S., Lilja H., Huland E., Huland H., Shurin G.V., Shurin M.R. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J. Urol. 2003, 170:2026-2030.
2. Abken H., Hombach A., Heuser C., Kronfeld K., Seliger B. Tuning tumor-specific T-cell activation: A matter of costimulation?. Trends Immunol. 2002, 23:240-245.
3. Armstrong A.C., Cheadle E.J., Hawkins R.E. Toward personalized immunotherapy for non-Hodgkin lymphoma: Targeting the idiotypic immunoglobulin. BioDrugs 2005, 19:289-297.
4. Aspinall R., Andrew D. Thymic involution in aging. J. Clin. Immunol. 2000, 20:250-256.
5. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 2004, 4:675-687.
6. Barnd D.L., Lan M.S., Metzgar R.S., Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 1989, 86:7159-7163.
7. Beck K.E., Blansfield J.A., Tran K.Q., Feldman A.L., Hughes M.S., Royal R.E., Kammula U.S., Topalian S.L., Sherry R.M., Kleiner D., Quezado M., Lowy I., Yellin M., Rosenberg S.A., Yang J.C. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006, 24:2283-2289.
8. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., Knolle P.A., Thomas R.K., von Bergwelt-Baildon M., Debey S., Hallek M., Schultze J.L. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
9. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
10. Burch P.A., Croghan G.A., Gastineau D.A., Jones L.A., Kaur J.S., Kylstra J.W., Richardson R.L., Valone F.H., Vuk-Pavlovic S. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate 2004, 60:197-204.
11. Carlos C.A., Dong H.F., Howard O.M., Oppenheim J.J., Hanisch F.G., Finn O.J. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J. Immunol. 2005, 175:1628-1635.
12. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
13. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997, 336:1855-1859.
14. Cheever M.A., Greenberg P.D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 1980, 125:711.
15. Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol. Immunother. 2006, 55:188-196.
16. Crespo F.A., Sun X., Cripps J.G., Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J. Leukoc. Biol. 2006, 79:586-595.
17. De Plaen E., Lurquin C., Van Pel A., Mariame B., Szikora J.P., Wolfel T., Sibille C., Chomez P., Boon T. Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tumantigen P91A and identification of the tum- mutation. Proc. Natl. Acad. Sci. USA 1988, 85:2274-2278.
18. Eberlein T.J., Rosenstein M., Rosenberg S.A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 1982, 156:385-397.
19. +) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 1999, 17:2521-2529.
20. Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., Wiltrout R.H., O'Shea J.J., Kudoh S., Klein E., et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993, 53:5613-5616.
21. Fredman P., Hedberg K., Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs 2003, 17:155-167.
22. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 2006, 6:383-393.
23. Gendler S.J., Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol. Med. 2001, 7:471-475.
24. Graziano D.F., Finn O.J. Tumor antigens and tumor antigen discovery. Cancer Treat. Res. 2005, 123:89-111.
25. Green L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 1999, 231:11-23.
26. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 1994, 24:1966-1973.
27. Hiltbold E.M., Alter M.D., Ciborowski P., Finn O.J. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol. 1999, 194:143-149.
28. Hiltbold E.M., Vlad A.M., Ciborowski P., Watkins S.C., Finn O.J. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 2000, 165:3730-3741.
29. Houghton J., Morozov A., Smirnova L., Wang T.C. Stem cells and cancer. Semin. Cancer Biol. 2007.
30. Huang A., Gilmour J.W., Imami N., Amjadi P., Henderson D.C., Allen-Mersh T.G. Increased serum transforming growth factor-betal in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin. Exp. Immunol. 2003, 134:270-278.
31. Italiano A. Targeting the epidermal growth factor receptor in colorectal cancer: Advances and controversies. Oncology 2006, 70:161-167.
32. Ito M., Minamiya Y., Kawai H., Saito S., Saito H., Nakagawa T., Imai K., Hirokawa M., Ogawa J. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 2006, 176:5637-5643.
33. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
34. Kaufman H.L., Wolchok J.D. Is tumor immunity the same thing as autoimmunity? Implication for cancer immunotherapy. J. Clin. Oncol. 2006, 24:2230-2232.
35. Kershaw M.H., Wang G., Westwood J.A., Pachynski R.K., Tiffany H.L., Marincola F.M., Wang E., Young H.A., Murphy P.M., Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 2002, 13:1971-1980.
36. Klein G., Sjogren H.O., Klein E., Hellstrom K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960, 20:1561-1572.
37. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., Ramanathapuram L.V., Arteaga C.L., Akporiaye E.T. Transforming growth factor beta inhibits the antigenpresenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003, 63:1860-1864.
38. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
39. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducingzeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 1996, 26:1308-1313.
40. Kyte J.A., Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., Gullestad H.P., Ryder T., Lislerud K., Hammerstad H., Gaudernack G. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006, 13:905-918.
41. Lee W.C., Chiang Y.J., Wang H.C., Wang M.R., Lia S.R., Chen M.F. Functional impairment of dendritic cells caused by murine hepatocellular carcinoma. J. Clin. Immunol. 2004, 24:145-154.
42. Levene A.P., Singh G., Palmieri C. Therapeutic monoclonal antibodies in oncology. J. R. Soc. Med. 2005, 98:146-152.
43. Li L., Neaves W.B. Normal stem cells and cancer stem cells: The niche matters. Cancer Res. 2006, 66:4553-4557.
44. Lin A.M., Hershberg R.M., Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol. Oncol. 2006, 24:434-441.
45. Lollini P.L., Cavallo F., Nanni P., Forni G. Vaccines for tumour prevention. Nat. Rev. Cancer 2006, 6:204-216.
46. Mehlen P., Puisieux A. Metastasis: A question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
47. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258:1795-1798.
48. Mocellin S., Mandruzzato S., Bronte V., Marincola F.M. Cancer vaccines: Pessimism in check. Nat. Med. 2004, 10:1278-1280.
49. Monti P., Leone B.E., Zerbi A., Balzano G., Cainarca S., Sordi V., Pontillo M., Mercalli A., Di Carlo V., Allavena P., Piemonti L. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J. Immunol. 2004, 172:7341-7349.
50. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
51. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003, 63:2535-2545.
52. Mukherjee P., Ginardi A.R., Madsen C.S., Tinder T.L., Jacobs F., Parker J., Agrawal B., Longenecker B.M., Gendler S.J. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj. J. 2001, 18:931-942.
53. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J.L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993, 53:5610-5612.
54. Nishimura Y., Chen Y.Z., Uemura Y., Tanaka Y., Tsukamoto H., Kanai T., Yokomizo H., Yun C., Matsuoka T., Irie A., Matsushita S. Degenerate recognition and response of human CD4+ Th cell clones: Implications for basic and applied immunology. Mol. Immunol. 2004, 40:1089-1094.
55. + T cells. Cancer Res. 2006, 66:571-580.
56. Orsini E., Guarini A., Chiaretti S., Mauro F.R., Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003, 63:4497-4506.
57. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy, and cancer vaccines. Curr. Opin. Immunol. 2004, 16:143-150.
58. + progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J. Immunother. 2003, 26:432-439.
59. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., Bergman B., Egevad L., Hellstrom M., Kiessling R., Masucci G., Wersall P., Nilsson S., Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 2004, 91:688-694.
60. Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Buggisch P., Witte J., Pichlmayr R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 1998, 16:1788-1794.
61. Rodriguez P.C., Zea A.H., Culotta K.S., Zabaleta J., Ochoa J.B., Ochoa A.C. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 2002, 277:21123-21129.
62. + T cells in patients with melanoma. J. Immunol. 2005, 175:6169-6176.
63. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
64. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001, 61:4756-4760.
65. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., Coleman D., Niedzwiecki D., Gilboa E., Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003, 63:2127-2133.
66. Syrengelas A.D., Chen T.T., Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 1996, 2:1038-1041.
67. Taheri F., Ochoa J.B., Faghiri Z., Culotta K., Park H.J., Lan M.S., Zea A.H., Ochoa A.C. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin. Cancer Res. 2001, 7:958s-965s.
68. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
69. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
70. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer?. Cancer Immunol. Immunother. 2004, 53:865-878.
71. Yanagimoto H., Takai S., Satoi S., Toyokawa H., Takahashi K., Terakawa N., Kwon A.H., Kamiyama Y. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin. Immunol. 2005, 114:52-60.
72. Yu M., Finn O.J. DNA vaccines for cancer too. Cancer Immunol. Immunother. 2006, 55:119-130.
73. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A., Rufer N., Lubenow N., Speiser D., Cerottini J.C., Romero P., Pittet M.J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res. 2004, 64:2865-2873.
74. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
75. Zuckerman A.J. Prevention of primary liver cancer by immunization. N. Engl. J. Med. 1997, 336:1906-1907.